drugset / Trial / NCT02527824
Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study will conduct a phase II study of triple combination with oxaliplatin, irinotecan, and S-1 as the first-line chemotherapy in patients with advanced biliary tract cancer.
Timeline
- Start
- 2015-03
- Primary completion
- 2016-08
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 65 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 80 mg/m2 | — |